Julie Asch, MD
Pediatric Hematology-Oncology · Salt Lake City, UTNPI 1083740070
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,990 of the $61,933 with a category attached, or 82.3%. Jazz Pharmaceuticals Inc. accounts for 93.4% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $51,322, more than ten times the $20 reported in 2019.
Across 63 payments — averaging $983.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$58K
- Amgen$2K
- Adaptive Biotechnologies Corporation$1K
- Incyte Corporation$173
- AstraZeneca$164
- Gilead$156
- plus $134 from 2 others
Across 40 payments — averaging $11,222 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$263K
- Servier Bioinnovation$183K
- Novartis$3K
What the payments were for
- Consulting fees$1,9333%
- Speaking & faculty fees$50,99082%
- Travel & lodging$7,11411%
- Food & beverage$1,7773%
- Education$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 44 | $57,819 |
| Amgen | 4 | $2,069 |
| Adaptive Biotechnologies Corporation | 7 | $1,419 |
| Incyte Corporation | 2 | $173 |
| AstraZeneca | 2 | $164 |
| Gilead | 2 | $156 |
| Novartis | 1 | $79 |
| Rigel Pharmaceuticals, Inc. | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,933 in reported general payments places this provider in the 85th percentile of 24 pediatric hematology-oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pediatric hematology-oncology in Salt Lake City
- Richard LemonsSalt Lake City$753K
- Luke MaeseSalt Lake City$332K
- Hassan YaishSalt Lake City$113K
- Ahmad RayesSalt Lake City$5K
- Nicholas WhippleSalt Lake City$3K
- Michell Lozano ChingaSalt Lake City$1K
- Soohee ChoSalt Lake City$948
- Joseph DolanSalt Lake City$295
- Mark FluchelSalt Lake City$235
- Elaine FanSalt Lake City$229
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.